Discovery and optimization of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor for the treatment of hemophilia A and B
{{output}}
We report the discovery and optimization of marstacimab, a novel monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), for the treatment of hemophilia A and B. Hybridoma and phage display approaches identified antibodies that blocked the TFPI: ... ...
